Ryan Taylor Anderson

Ryan Anderson’s work focuses on improving health care and patient outcomes by developing, testing, and evaluating clinical quality measures and biomedical research projects that impact health policy. His background working in academic research, in the fields of oncology and viral hepatitis, enables him to inform and evaluate health policy topics associated with drug development, medicine, and disease.

Since joining Mathematica, Anderson has led measure testing to develop a novel patient-reported outcomes measure for lung cancer patients, a collection of pathology measures in preparation for the Centers for Medicare & Medicaid Services (CMS) Qualified Clinical Data Registry self-nomination, and managed testing activities to maintain National Quality Forum measure endorsement. He is an intellectual lead and subject matter expert for various quality measures included in CMS’s Quality Payment Program. Anderson has also worked on a variety of health policy projects, covering topics such as possibly avoidable utilization rates and unit price adjustments for hospital budgets, medical and adult-use cannabis, microsimulation modeling to predict Medicaid enrollment, and public health responses to the COVID-19 pandemic.

Before joining Mathematica, Anderson was a senior research associate and Gilead Fellow in Hepatitis B at the Forum for Collaborative Research. During his time there, he managed projects that brought together a group of drug and diagnostic development experts to deliberate on and provide recommendations for the treatment of chronic hepatitis B infection and HIV pre-exposure prophylaxis. While at the University of Colorado, he developed hypotheses, designed and performed experiments, and published primary scientific articles with a team of researchers focused on preclinical drug development for the treatment of head and neck cancers and the identification of true cancer stem cell populations. His work has been published in leading peer-reviewed journals including Gastroenterology, Clinical Cancer Research, and Molecular Oncology. He holds a M.P.H. in health policy and management from the University of California, Berkeley.